Search Results

You are looking at 1 - 5 of 5 items for

  • Author or Editor: William G. Ryan x
  • Refine by Access: All Content x
Clear All Modify Search


Objective—To generate data on the effects of firocoxib administration to horses with osteoarthritis.

Animals—Client-owned horses with signs of lameness and joint pain associated with osteoarthritis.

Procedures—Firocoxib was administered as an oral paste (0.1 mg/kg, q 24 h) for 14 days. Assessments were performed on day 0 (baseline) and days 7 and 14.

Results—390 of 429 horses from 80 sites in 25 states met the criteria for analysis. Quarter Horse and Thoroughbred were the 2 most commonly represented breeds, comprising half of the study population. Signs of musculoskeletal pain or lameness attributed to osteoarthritis were diagnosed in a single joint in 197 (197/390 [50.5%]) horses and in multiple joints in 193 (193/390 [49.5%]) horses. In those with involvement of a single joint, the tarsus was the most frequently affected joint (79/197 [40.1 %]). Among the 390 horses with complete lameness data, improvement was reported in approximately 80% by day 14. Investigators rated 307 (78.7%) horses as improved, whereas owners or handlers rated 316 (81.0%) horses as improved at the termination of the study. Horses treated with firocoxib paste had significant improvement in lameness scores from baseline values. Improvement was most rapid within the first 7 days after starting treatment and continued, albeit at a slower rate, through treatment day 14.

Conclusions and Clinical Relevance—Firocoxib significantly improved lameness scores throughout the 14-day period with few adverse effects. Firocoxib can be a safe cyclooxygenase-2–specific NSAID for the treatment of musculoskeletal pain and lameness associated with osteoarthritis.

Full access
in American Journal of Veterinary Research


To assess parasite control and weight gain after administration of an ivermectin sustained-release bolus over 135 days to calves grazing in the midwestern United States.


Replicated pasture study.


56 Bos taurus calves.


Calves were matched for body weight and randomly allocated to remain untreated or to receive an ivermectin sustained-release bolus before turnout on day 0. Calves were grazed by treatment group on 8 pastures (4 replicates). Body weights and fecal egg counts were recorded on days −1 and 28, and then at 28-day intervals until day 168.


Parasitism was not clinically evident prior to or during the study. In treated calves, mean fecal egg counts were at or near 0 at all posttreatment evaluations. Although the mean egg count exceeded 20 ova/g only once in control calves, the cumulative egg output was > 42 million/calf. For the treated group, it was < 0.1% of this number. Mean total weight gain was 33.9 kg (74.6 lb) greater for ivermectin-treated calves than for untreated control calves (P < 0.02); a 34% increase.

Clinical Implications

Fecal trichostrongyle eggs from calves can accumulate over a grazing season to provide enormous potential for augmenting pasture infectivity. An ivermectin sustained-release bolus (administered to calves being placed on pasture) controls parasitism, limits pasture infectivity, and can substantially influence growth by limiting the impact of subclinical parasitism. (J Am Vet Med Assoc 1997;211:754–756)

Free access
in Journal of the American Veterinary Medical Association



To determine the efficacy of ivermectin (IVM) and milbemycin oxime (MBO) against induced heartworm infection, where monthly treatment is started 3 or 4 months after infection, and to monitor microfilaremia and antigenemia.


21 heartworm-naive Beagles.


Each of 21 dogs was given 50 infective larvae of Dirofilaria immitis by SC inoculation. One group of 5 dogs served as nonmedicated controls, 2 groups of 5 dogs received IVM at 6 μg/kg of body weight or MBO at 500 μg/kg for 12 months beginning at postinfection (PI) month 4, and 2 groups of 3 dogs received IVM or MBO for 13 months beginning at PI month 3. Blood collected at intervals not >1 month beginning at PI month 4 was examined for microfilariae and antigen. Dogs were euthanatized at PI month 16.


Adult worm counts, relative to controls, were reduced in the 4-month treatment groups by 95.1 (P < 0.01) and 41.4% for IVM and MBO, respectively. The difference between the IVM and MBO groups was significant (P < 0.01). Live worms were found in all MBO-treated (range, 8 to 27) and control dogs (range, 12 to 39) and in 3 of 5 IVM-treated dogs (range, 2 to 4). In the 3-month treatment groups, worm counts were reduced by 97.7 (P < 0.01) and 96.8% (P < 0.01) for IVM and MBO, respectively. Microfilariae were seen in all control dogs and in only 2 of the 16 treated dogs. The antigen response of MBO-treated dogs in the 4-month treatment group was only slightly weaker than that for control dogs. In all other treated dogs, this response was delayed and weaker.


Ivermectin is highly (≥ 95%) and significantly more effective than MBO against induced heartworm infection when 1 year of monthly prophylactic dosing is started 4 months after infection.

Clinical Relevance

In some cases of owner compliance failure, monthly administration of IVM gives a high level of protection against young adult heartworms. (Am J Vet Res1996;57:1189-1192)

Free access
in American Journal of Veterinary Research